BACKGROUND: Quantification of Circulating Tumor Cells (CTCs) as a prognostic marker in metastatic colorectal cancer (mCRC) has already been validated and approved for routine use. However, more than quantification, qualification or characterization of CTCs is gaining importance, since the genetic characterization of CTCs may reflect, in a real time fashion, genetic profile of the disease. OBJECTIVE: To characterize KRAS mutations (codon 12 and 13) in CTCs from patients with mCRC and to compare with matched primary tumor. Additionally, correlate these mutations with clinical and pathological features of patients. METHODS: Blood samples were collected from 26 patients with mCRC from the AC Camargo Cancer Center (São Paulo-Brazil). CTCs were isolated by ISET technology (Isolation by Size of Epithelial Tumors; Rarecells Diagnostics, France) and mutations analyzes were performed by pyrosequencing (QIAGEN). RESULTS: KRAS mutation was detected in 7 of the 21 cases (33%) of samples from CTCs. In matched primary tumors, 9 of the 24 cases (37.5%) were found KRAS mutated. We observed that 5 of the 9 samples with KRAS mutation in their primary tumor had also KRAS mutation in CTCs, meaning a concordance of 71% of matched cases (P = 0.017). KRAS mutation neither on primary tumor nor in CTCs was associated with clinical-pathological parameters analyzed. CONCLUSION: Faced with a polyclonal disease like colorectal cancer, which is often treated with alternating and successive lines of chemotherapy, real time genetic characterization of CTCs, in a fast and feasible fashion, can provide important information to clinical management of metastatic patients. Although our cohort was limited, it was possible to show a high grade of concordance between primary tumor and CTCs, which suggests that CTCs can be used as surrogate of primary tumors in clinical practice, when the knowledge of mutation profile is necessary and the primary tumor is not available.
BACKGROUND: Quantification of Circulating Tumor Cells (CTCs) as a prognostic marker in metastatic colorectal cancer (mCRC) has already been validated and approved for routine use. However, more than quantification, qualification or characterization of CTCs is gaining importance, since the genetic characterization of CTCs may reflect, in a real time fashion, genetic profile of the disease. OBJECTIVE: To characterize KRAS mutations (codon 12 and 13) in CTCs from patients with mCRC and to compare with matched primary tumor. Additionally, correlate these mutations with clinical and pathological features of patients. METHODS: Blood samples were collected from 26 patients with mCRC from the AC Camargo Cancer Center (São Paulo-Brazil). CTCs were isolated by ISET technology (Isolation by Size of Epithelial Tumors; Rarecells Diagnostics, France) and mutations analyzes were performed by pyrosequencing (QIAGEN). RESULTS:KRAS mutation was detected in 7 of the 21 cases (33%) of samples from CTCs. In matched primary tumors, 9 of the 24 cases (37.5%) were found KRAS mutated. We observed that 5 of the 9 samples with KRAS mutation in their primary tumor had also KRAS mutation in CTCs, meaning a concordance of 71% of matched cases (P = 0.017). KRAS mutation neither on primary tumor nor in CTCs was associated with clinical-pathological parameters analyzed. CONCLUSION: Faced with a polyclonal disease like colorectal cancer, which is often treated with alternating and successive lines of chemotherapy, real time genetic characterization of CTCs, in a fast and feasible fashion, can provide important information to clinical management of metastatic patients. Although our cohort was limited, it was possible to show a high grade of concordance between primary tumor and CTCs, which suggests that CTCs can be used as surrogate of primary tumors in clinical practice, when the knowledge of mutation profile is necessary and the primary tumor is not available.
Entities:
Keywords:
KRAs mutation; circulating tumor cell; colorectal cancer
Authors: Javier Sastre; Marta Vidaurreta; Auxiliadora Gómez; Fernando Rivera; Bartomeu Massutí; Margarita Reboredo López; Albert Abad; Manuel Gallen; Manuel Benavides; Enrique Aranda; Eduardo Díaz Rubio Journal: Clin Colorectal Cancer Date: 2013-09-05 Impact factor: 4.481
Authors: Bianca Mostert; Yuqiu Jiang; Anieta M Sieuwerts; Haiying Wang; Joan Bolt-de Vries; Katharina Biermann; Jaco Kraan; Zarina Lalmahomed; Anne van Galen; Vanja de Weerd; Petra van der Spoel; Raquel Ramírez-Moreno; Cornelis Verhoef; Jan N M Ijzermans; Yixin Wang; Jan-Willem Gratama; John A Foekens; Stefan Sleijfer; John W M Martens Journal: Int J Cancer Date: 2013-02-09 Impact factor: 7.396
Authors: Matthew G Krebs; Jian-Mei Hou; Robert Sloane; Lee Lancashire; Lynsey Priest; Daisuke Nonaka; Tim H Ward; Alison Backen; Glen Clack; Andrew Hughes; Malcolm Ranson; Fiona H Blackhall; Caroline Dive Journal: J Thorac Oncol Date: 2012-02 Impact factor: 15.609
Authors: Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544
Authors: Christin Gasch; Thomas Bauernhofer; Martin Pichler; Sabine Langer-Freitag; Matthias Reeh; Adrian M Seifert; Oliver Mauermann; Jakob R Izbicki; Klaus Pantel; Sabine Riethdorf Journal: Clin Chem Date: 2012-11-07 Impact factor: 8.327
Authors: Stephan E Baldus; Karl-L Schaefer; Rainer Engers; Dinah Hartleb; Nikolas H Stoecklein; Helmut E Gabbert Journal: Clin Cancer Res Date: 2010-01-26 Impact factor: 12.531
Authors: Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein Journal: Nature Date: 2012-06-28 Impact factor: 49.962
Authors: L Khoja; A Backen; R Sloane; L Menasce; D Ryder; M Krebs; R Board; G Clack; A Hughes; F Blackhall; J W Valle; C Dive Journal: Br J Cancer Date: 2011-12-20 Impact factor: 7.640
Authors: Emne A Abdallah; Alexcia C Braun; Bianca C T C P Flores; Laís Senda; Ana Cláudia Urvanegia; Vinicius Calsavara; Victor Hugo Fonseca de Jesus; Maria Fernanda Arruda Almeida; Maria Dirlei Begnami; Felipe J F Coimbra; Wilson Luiz da Costa; Diana Noronha Nunes; Emmanuel Dias-Neto; Ludmilla T Domingos Chinen Journal: Oncologist Date: 2019-03-07
Authors: Matthew W Rosenbaum; Christy E Cauley; Birte Kulemann; Andrew S Liss; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Sarah P Thayer; Martha B Pitman Journal: Cancer Cytopathol Date: 2017-03-03 Impact factor: 5.284
Authors: Andrea Ravelli; James M Reuben; Francesco Lanza; Simone Anfossi; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Paola Brambilla; Manuela Milani; Daniele Spada; Paolo Pedrazzoli; Massimo Martino; Alberto Bottini; Daniele Generali Journal: Tumour Biol Date: 2015-08-26
Authors: Manjima Dhar; Edward Pao; Corinne Renier; Derek E Go; James Che; Rosita Montoya; Rachel Conrad; Melissa Matsumoto; Kyra Heirich; Melanie Triboulet; Jianyu Rao; Stefanie S Jeffrey; Edward B Garon; Jonathan Goldman; Nagesh P Rao; Rajan Kulkarni; Elodie Sollier-Christen; Dino Di Carlo Journal: Sci Rep Date: 2016-10-14 Impact factor: 4.379
Authors: Mylène Sebagh; Marc-Antoine Allard; Nelly Bosselut; Myriam Dao; Eric Vibert; Maïté Lewin; Antoinette Lemoine; Daniel Cherqui; René Adam; Antonio Sa Cunha Journal: Oncotarget Date: 2016-04-19